The biotech sector is thriving as it advances in commercializing therapies for rare and new diseases, addressing unmet medical needs. Driven by rising global demand for quality healthcare, targeted treatments, and advanced technology, the industry's growth positions it as a promising investment opportunity for those seeking value in the healthcare landscape.
Hence, investors could consider buying undervalued biotech stocks: Harmony Biosciences Holdings, Inc. (HRMY), United Therapeutics Corporation (UTHR), and BioMarin Pharmaceutical Inc. (BMRN), which look ready for a breakout.
